Also known as: severe hypoglycemia
Sequel Med Tech reported positive pivotal trial results for its twiist Automated Insulin Delivery System in adults with type 2 diabetes. The 13-week study showed meaningful improvements in HbA1c and time in range with no severe hypoglycemia events. Separately, Sequel and Senseonics launched the twiist system integrated with Eversense 365 CGM across the U.S.
FDA approves MannKind's Afrezza inhaled insulin for children aged 6+ with type 1 and type 2 diabetes. Separately, an updated label provides new starting dose guidance for adults switching from injections or insulin pumps.
C-peptide is described as a key biomarker for beta cell function in type 1 diabetes and a potential surrogate endpoint for drug approval. Current trial endpoints remain difficult for disease-modifying therapies.
A multicenter retrospective cohort study of 17 patients with type 2 diabetes and end-stage renal disease found injectable semaglutide was associated with descriptive changes in glycemic control and body weight. No cardiovascular deaths, nonfatal myocardial infarctions, or nonfatal strokes were observed during follow-up.
The congenital hyperinsulinism pipeline includes 4+ active companies and 4+ therapies across clinical and nonclinical stages. Zealand Pharma advanced dasiglucagon in January 2026, while RZ358 is in Phase III evaluation.
New clinical evidence demonstrates that combining SGLT2 inhibitors with GLP-1 receptor agonists provides additive benefits for type 2 diabetes patients, while machine learning tools help personalize therapy selection.
Recent research explores outcomes when patients stop GLP-1 medications and finds pharmacist-led interventions can help older adults avoid dangerous low blood sugar episodes.
Xenetic Biosciences reported a net loss of $2.7 million for 2025 while advancing its DNase-based cancer therapy toward clinical trials, ending the year with $7.9 million in cash. Xeris Biopharma will announce its 2025 financial results on March 2, 2026.
Amylyx Pharmaceuticals is advancing avexitide toward potential FDA approval for post-bariatric hypoglycemia, with Phase 3 LUCIDITY trial results expected in Q3 2026 and a cash runway extending into 2028.
Study of 3600 older adults with type 1 diabetes across US and European registries reveals significant gaps in guideline-recommended cardiovascular therapies and diabetes technology use despite high disease burden.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07614139 |
Continuous Glucose Monitoring Alerts, Accuracy, and Patient Outcomes in Adults With Inherited Metabolic Disorders |
COMPLETED | NA |
| NCT07375615 |
Continous Glucose Monitoring in Neonates at Risk of Hypoglycaemia- a Feasibility Study |
COMPLETED | |
| NCT07329985 |
FEAR of HYPOGLYCEMIA in PATIENTS WITH DIABETES |
NOT_YET_RECRUITING | |
| NCT07286500 |
"Sexual Activity and Hypoglycemia Risk in Adults With Type 1 or Type 2 Diabetes Using Insulin Therapy and Continuous Glucose Monitoring" |
RECRUITING | |
| NCT07233421 |
Frequency of Hypoglycemia in Children With Beta-blocker Treated Long QT-syndrome |
ENROLLING_BY_INVITATION | NA |
| NCT07132476 |
The Construction and Validation of a Risk Prediction Model for Perioperative Hypoglycemia in Digestive Endoscopy |
COMPLETED | |
| NCT07082478 |
External Carotid Blood Flow in Individuals With Post-Bariatric Hypoglycemia |
RECRUITING | |
| NCT06986603 |
Glucagon Dose-Response in Patients With Post-Bariatric Hypoglycemia |
ACTIVE_NOT_RECRUITING | PHASE4 |
| NCT06893341 |
Monitoring Exhaled Breath to Noninvasively Detect Glycemic Events |
RECRUITING | NA |
| NCT06657287 |
Postprandial Hypotension and Insulin Levels |
COMPLETED |
